<DOC>
	<DOCNO>NCT02883452</DOCNO>
	<brief_summary>A new subcutaneous infliximab formulation develop Celltrion , Inc. alternative intravenous regimen subcutaneous infliximab injection typically take less 2 minute . The availability subcutaneous formulation infliximab would increase treatment option available patient , particularly wish self-administer therapy [ Jackisch et al . 2014 ] . This Phase 1 randomize , open-label , multicenter , parallel-group study design evaluate efficacy , pharmacokinetics safety CT-P13 SC CT-P13 IV patient active CD active UC .</brief_summary>
	<brief_title>A Phase I Study Evaluate Pharmacokinetics , Efficacy Safety Between Subcutaneous CT-P13 Intravenous CT-P13 Patients With Active Crohn 's Disease Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patient male female age 18 75 year old , inclusive . Patient adequate renal hepatic function Screening Patient ability comprehend full nature purpose study , include possible risk side effect , cooperate investigator , understand verbal and/or write instruction , comply requirement entire study . Patient previously receive biological agent treatment Crohn 's disease Ulcerative colitis and/or TNFÎ± ( tumor necrosis factor alpha ) inhibitor treatment disease . Patient allergy excipients infliximab , murine and/or human protein , patient hypersensitivity immunoglobulin product . Patient current past history drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>